Related Experiment Video
Updated: Jun 1, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
[Canakinumab, a monoclonal antibody against IL-1β, with potential utility in different inflammatory processes]
1Servicio de Farmacología Clínica, Unidad de Evaluación, Soporte y Prevención, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Hospital Clínic, Barcelona, España. xcarne@clinic.ub.es
Abstract:
Canakinumab is a fully human monoclonal antibody targeted at IL-1β which has shown to be effective in the control the symptoms of patients affected by CAPS and other autoinflammatory diseases. Its effect is rapid and sustained. In clinical trials conducted up until now, the most common adverse effects reported with the use of this drug have been different types of infections, migraines and vertigo.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Ulcerative Colitis

